To determine the influence of nitric oxide (NO) on vascular tone during fetal development, timed pregnant rats received the NO synthase inhibitor p-nitro-L-arginine methyl ester for consecutive 4, 7, or 14 d before parturition (postorganogenesis). Offspring demonstrated limb reduction defects (incidence, 53%) involving either or both hindlimbs, whereas forelimbs were uniformly spared. Defects were dose-dependent but independent of the duration of administration occurring with equal frequency in 4-, 7-, and 14-d treatment groups. Histologic analysis revealed features characteristic of vascular disruption with hemorrhagic necrosis and loss of structure. The defects were prevented by concurrent maternal administration of L-arginine or the NO donors S-nitroso-N-acetyl-penicillamine and sodium nitroprusside. Defects were not seen after prenatal treatment with aminoguanidine. To study basal and agonist-mediated NO release, newborn femoral and brachial arteries were cannulated with a glass micropipette under constant pressure, and changes in intraluminal diameter (micrometers) were measured in response to acetylcholine and the NO synthase inhibitor Nu-nitro-L-arginine.
NO is a potent vasodilator produced by vascular endothelium and smooth muscle from the amino acid L-arginine by NOS. Several isoforms of NOS have been isolated from brain (type I), macrophages (type 11), and vascular endothelium (type 111). Both the brain and endothelial isoforms are calcium1 calmodulin-dependent enzymes which are expressed under physiologic conditions (constitutive). The inducible isoform, in contrast, is calcium/calmodulin-independent and is expressed in vascular smooth muscle solely in response to various cytokines or endotoxins. The physiologic regulation of vascular tone by the constitutive isoform generally occurs through two distinct pathways: continuous or basal NO release and that which is generated in response to various agonists or physical
Newborn femoral and brachial vessels demonstrated a dramatic (59%) decrease in resting diameter compared with adult vessels (16%). These findings suggest that basal NO release is upregulated during fetal development concurrent with the processes that increase maternal NO release. The data also suggest that up-regulation of NO release occurs throughout the fetal systemic circulation and is not restricted to hindlimbs. This is the first study to demonstrate inhibition of NO release in the pathogenesis of limb reduction defects. (Pediatr Res 38: 905-911, 1995) Abbreviations NO, nitric oxide NOS, nitric oxide synthase LRD, limb reduction defects L-NAME, p-nitro-L-arginine methyl ester L-NNA, N,-nitro-L-arginine SNP, sodium nitroprusside SNAP, S-nitroso-acetylpenicillamine stimuli such as shear stress (1, 2) . A number of L-arginine analogs such as L-NAME and L-NNA have been identified which effectively inhibit both the constitutive and inducible isoforms. Aminoguanidine predominately inhibits the inducible NOS isoform.
The mechanisms that regulate the changes in vascular tone that characterize the dynamic nature of the perinatal circulation are incompletely understood. Even less is known about factors governing vascular tone during normal fetal growth and development. Common complications of premature birth such as intraventricular hemorrhage, persistent fetal circulation, and necrotizing enterocolitis are believed to be related to pathology of the fetal vasculature. To determine the role of endothelial NO release during normal fetal growth and development, we recently investigated the effects of chronic early third trimester inhibition of NO release with the L-arginine analog, L-NAME, in timed pregnant Sprague-Dawley rats. Although L-NAME produced significant intrauterine growth retardation (3), the most remarkable findings were LRD involving the hindlimbs.
PIERCE
The hindlimbs demonstrated features characteristic of vascular disruption with evidence of grossly hemorrhagic tissue and loss of structure. Furthermore, although either or both hindlimbs were involved, the forelimbs were uniformly spared. Although LRD have been produced by several teratogens (4), the effect is almost always seen early in the first trimester period of organogenesis when the fetus is most vulnerable to birth defects (5). The production of LRD by L-NAME during the third trimester was an unusual teratogenic effect with several intriguing implications regarding the role of endothelial NO release in the systemic circulation during late fetal development.
Increased maternal and placental NO release during pregnancy has been previously demonstrated (6, 7). Our preliminary findings suggested that NO release may also be increased during late fetal development, specifically in the hindlimbs. The preliminary data required further investigation of the teratogenic effects of L-NAME and further determination of a process specific for inhibition of fetal endothelial NO release. L-NAME is a nonspecific inhibitor of both inducible and constitutive isoforms. In addition, L-arginine is a semiessential amino acid, and disruptions might develop due to inhibition of L-arginine uptake during the relative period of rapid growth characteristic of the third trimester. Both in vivo and in vitro studies were undertaken with the following specific goals: I ) to determine the effect of both the dose and duration of L-NAME administration on the incidence LRD; 2) to determine whether the LRD were specific for inhibition of constitutive NOS and endothelial NO release as suggested by the histologic finding of hemorrhagic necrosis; and 3) to determine whether basal or acetylcholine-mediated NO release is increased in isolated hindlimb vessels from newborns compared with adult animals which might explain vulnerability to vascular disruptions.
METHODS
All animal treatments and procedures were preapproved by the Louisiana State University Medical School Committee on Research Animal Welfare. They were maintained in the Animal Care Facilities of the Louisiana State University Medical School under veterinary supervision on standard rat pellet diet ad libitum and kept on a 12-h lightldark cycle. Rats were chosen as the study model because they manifest hemodynamic alterations during gestation closely resembling those of a gravid human (8). All chemicals were obtained from Sigma Chemical Co. (St. Louis, MO). Acetylcholine and SNP were prepared fresh daily in normal saline stock solutions. U46619 and indomethacin stock solutions were prepared in 95% ethanol. Ethanol vehicle from stock solutions did not affect vascular tone. L-NNA was dissolved in acidified normal saline with a final pH adjusted to 7.0.
In Vivo Studies
Timed pregnant rats (Holtzman, Harlan Sprague-Dawley) were obtained on gestational d 6 of a 22-d gestation. Four to six dams were randomly assigned to the treatment groups described below (10-16 pups per litter). The in vivo studies were conducted in four parts. Part 1 determines whether the incidence of LRD increases with dose and duration of prenatal L-NAME treatment (i.e. second through third trimester (14 prenatal days) versus late third trimester (4 prenatal days). Part 2 determines whether LRD occur with postnatal L-NAME treatment. Part 3 determines whether concurrent treatment with the NO precursor (L-arginine) or NO donors SNP or SNAP alters the incidence of LRD produced by L-NAME. Part 4 determines whether selective inhibition of inducible NOS with aminoguanidine results in LRD.
Part 1: Dose and duration of NOS inhibition with L-NAME and LRD. The dose range of L-NAME used in this study was based on our previous experience with doses of L-NAME which reduce the elevated NO production associated with experimental inflammatory bowel disease (9), as well as a number of reports evaluating hypertension induced by chronic reductions of NO synthesis (10, 11). The oral route of administration of the NOS inhibitors has been shown to be a simple and reliable approach to the chronic reduction of NOS in vivo (9-1 1). Daily fluid consumption was followed in two to three animals per cage and an estimated daily dose of L-NAME between 54 to 180 mgkgld was obtained with concentrations of 0.3 and 1.0 mg1mL L-NAME in the drinking water, respectively. Dams were studied at 6 through 19 and 16 through 19 d of gestation, corresponding to 14 and 4 d of treatment, respectively. For each gestational period studied, dams were randomly assigned one of three treatment groups (0.3 and 1.0 mg1mL L-NAME or water only controls). On gestational d 20, dams were given an overdose of intraperitoneal sodium pentobarbital. Fetuses were removed from the uterus and inspected for LRD. LRD were defined by partial or complete reduction in the size of a limb and by the presence of structural or morphologic abnormalities. Control and altered limbs were fixed in 10% paraformaldehyde, paraffin-embedded, and stained with hematoxylin and eosin for histologic evaluation.
Part 2: Postnatal L-NAME. Because the quantity of L-NAME excreted in breast milk is not known, two different routes of administering L-NAME were studied in newborn rats. In the first, L-NAME was administered for 14 postnatal days indirectly in maternal breast milk (1.0 mg1mL of maternal drinking water). In a second group, L-NAME was administered through daily intraperitoneal injection (180 mglkg) in 0.1 mL of saline. A third group served as water only controls in the breast-fed group, and a fourth group received intraperitoneal injections of 0.1 mL saline. Newborns were examined daily for LRD.
Part 3: L-NAME plus L-arginine, SNP, or SNAP. Timed pregnant rats were randomly assigned to one of four treatment groups (timing and doses based on results of part 1). The first received L-NAME at 1.0 mg1mL plus the NO precursor Larginine at 0.03 gImL, which approximates 180 mglkgld and 5.4 gkgld, respectively, in the drinking water. The second group received L-NAME at 1.0 mg/mL in the drinking water plus the NO donor SNP, by s.c. implantation of osmotic minipumps (Alza Corp., Palo Alto, CA) at 1.0, 3.0, and 10 pglkglmin. The third group received L-NAME at 1.0 mg1mL in the drinking water plus the NO donor SNAP, by s.c. implantation of osmotic minipumps at 1.0, 3.0, and 10 pglkglmin. The fourth group was a water-only control. After 7 d of prenatal treatment (gestational d 13-19), on gestational d 20 dams received an overdose of intraperitoneal sodium pentobarbital. Fetuses were removed and inspected for LRD.
Part 4: Selective inhibition of inducible NOS with aminoguanidine. Pregnant dams were randomly assigned to one of two treatment groups. The first received the selective inducible NOS inhibitor, aminoguanidine, at 1.0 mg1mL for 7 prenatal days (gestational d 13-19), which approximates 180 mgkgld. The second group was a water-only control. On gestational d 20, dams were given an overdose of intraperitoneal sodium pentobarbital. Fetuses were removed and inspected for LRD.
In Vitro Studies
Adult and newborn rats (3-7 d of age) were killed after intraperitoneal sodium pentobarbital, and either the femoral or brachial artery was rapidly removed and placed in Krebsbicarbonate buffer at 3-5°C equilibrated with a 95% 0,/5% CO, gas mixture. Vessels were carefully cleaned of surrounding fat and adventitia and transferred to the myograph chamber. Vessels were cannulated with a glass micropipette of known internal diameter and then gently flushed to remove remaining blood before the distal end was tied with surgical nylon monofilament to create a blind pouch configuration. Vessels were then allowed to equilibrate for 45 min as temperature was slowly raised to 37OC and intraluminal pressure was slowly raised to 30 mm Hg for newborn vessels and 100 mm Hg for adult vessels. These pressures were previously determined to provide maximal response to KC1 contracture. Cannulated vessels were illuminated on an inverted microscope and displayed through a camera connected to a dimension analyzer (Living Systems Inc., Burlington, VT) that provides a constant digital display of lumen diameter and wall thickness. A microliter peristaltic pump with an automatic pressure servocontrol maintained constant intraluminal pressure throughout the study ( t 1 mm Hg). After equilibration, vessels were required to maintain a stable intraluminal pressure (manual setting of pressure servocontrol) as assurance that no flow or leaks were present. Both pressure and lumen diameter were continuously recorded on a strip chart recorder. All chemicals were added to the buffer superfusion reservoir and allowed to recirculate through the myograph chamber (total volume, 80 mL). The myograph chamber was continuously perfused at 37OC with Kreb's bicarbonate buffer equilibrated with 21% O,, 5% CO,, and balance with N, at pH 7.4 which contained (in mM) 110 NaC1, 5 KC1, 2.5 CaCl, 1 MgSO,, 1 KHPO,, 24 NaHCO,, 10 dextrose, 0.02 EDTA, and 0.01 indomethacin. Both superfusate flow rate and gas were adjusted to maintain pH and temperature which were continuously monitored through a YSI temperature probe directly in the myograph and a pH probe placed in the reservoir. Vessels studied in both newborn and adult animals demonstrated passive dilation to increments in intraluminal pressure with no significant myogenic response.
As a measure of agonist-independent maximal contractile response all vessels were initially challenged with 60 mM KC1. Vessels that demonstrated less than 50% decrease in resting diameter were discarded. Higher doses of KC1 completely obliterated intraluminal diameter in all vessels. After washout of KC1, all vessels were submaximally preconstricted with 30 nM of the thromboxane mimic U46619. U46619 also served as a basis for comparison of agonist-mediated responses with the change in resting diameter produced by L-NNA. To analyze basal NO release after washout of U46619, vessels were challenged with incremental doses of L-NNA. Acetylcholine served to determine endothelial, receptor-mediated NO release, respectively. Inasmuch as acetylcholine is not a pure NO agonist but activates additional mechanisms, NO-specific responses were quantified by subsequent inhibition of peak acetylcholine responses with L-NNA. SNP responses were determined as a measure of endothelium-independent, guanylate cyclase-mediated tone.
Statistical analysis. Incidence of disruptions in the treated versus untreated rat pups were compared by 2 testing (12).
For in vitro studies, vessel responses were compared with a two-way analysis of variance where a p < 0.05 value was considered to represent a statistically significant difference between the compared values. Only one vessel from each animal was studied.
RESULTS

In vivo studies.
Maternal health did not appear to be compromised by the NOS inhibitors. Maternal weight gain was comparable in each group, averaging 14.8 t 1.2 g/d. Fluid consumption was also comparable in each group, averaging 184 27 mL/kg/d. No LRD were observed in fetuses of control dams (>500 control fetuses). The incidence of LRD in fetuses prenatally treated with the selective inhibitor of the inducible NOS isoform, aminoguanidine, was also zero (out of 84 fetuses). In all aspects, aminoguanidine-treated animals could not be distinguished from control animals. L-NAMEinduced LRD were influenced by the dose administered (0.3 versus 1.0 mg1mL) ( p > 0.05) but not by the duration of prenatal exposure, occurring with equal frequency after 4,7, or 14 d of prenatal treatment (Fig. 1) . The disruptions were found only in the hindlimbs, and it was observed in either leg or both, varying in severity from disruptions of toes to complete absence of proximal thigh ( Fig. 2A) . Histologically the L-NAMEtreated limbs revealed a hemorrhagic necrosis, with a marked cellular infiltration and loss of structure (Fig. 2B) .
Supplementation with the NO precursor, L-arginine, to dams receiving 1.0 mg1mL of L-NAME for 7 prenatal days completely inhibited these disruptions (0 of 96 fetuses). The addition of the NO donors, SNP and SNAP, to the dams receiving L-NAME significantly reduced the incidence of disruptions in a dose-dependent fashion (Fig. 3 , p < 0.05). LRD were not seen during the postnatal period (directlintraperitoneal: 0 of 62 newborns; indirecthreast milk: 0 of 75). In all parts of the study there were no differences in the number of pups per litter or stillbirths in any treatment group.
In vitro studies. Adult and newborn femoral vessels demonstrated stable resting diameters of 609 & 11 and 177 t 9 pm, respectively. Newborn brachial arteries were anatomically somewhat larger than hindlimb vessels with a stable resting diameter of 258 +-11 p m (n = 12 for each vessel group). 
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Vessels from both age groups demonstrated steady and sustained reductions in resting diameter in response to incremental doses of L-NNA. Most reports on basal NO release have demonstrated little (<20%) or no response to L-arginine analogs in resting vessels (2). In adult femoral arteries L-NNA produced a maximal 16% decrease in resting diameter which is also of similar magnitude to what has been reported in cannulated nonperfused arterioles in rat cremaster muscle (13). Compared with adult vessels, newborn femoral and brachial arteries demonstrated a considerably larger response to L-NNA with a 55 and 59% decrease in resting diameter, respectively (Fig. 4) . Further evidence of the age-related difference in basal NO release is apparent when the L-NNA response is compared with the vasoconstriction produced by 30 nM U46619 and 60 mm KC1 (Fig. 5) . The response to L-NNA is comparable in magnitude to the response to U46619 in both newborn vessels, whereas in adult femoral arteries the L-NNA response in substantially less in comparison to U46619 (p < 0.05). Relaxation responses to SNP were quantitatively similar in all three arteries at each concentration (Fig. 6A) . Peak relaxation responses to acetylcholine were also quantitatively similar in all three vessels (Fig. 6B) . Acetylcholine is known to produce endothelial dependent vasodilatation through NO release and activation of an endothelial hyperpolarization factor (14). To determine that component of the acetylcholine relaxation response specifically mediated by NO release, vessels were subsequently challenged with L-NNA after the peak response to acetylcholine. Both newborn brachial and femoral vessels demonstrated essentially complete (>90%) inhibition or reversal of acetylcholine relaxation. Adult femoral vessels in contrast demonstrated only a modest (50%) inhibition of acetylcholine response (Fig. 7) . The L-NNA-mediated inhibition of acetylcholine responses bear striking resemblance to the change in resting diameters produced by L-NNA. In addition, the L-NNA responses did not go below baseline tone which might be expected in response to cumulative inhibition of basal and agonist mediated NO release. As a whole this suggests that the observed responses may primarily reflect differences in basal and not agonist-mediated NO release.
DISCUSSION
The effects of most teratogens on embryogenesis and fetal development usually occur at a specific time during gestation that defines a vulnerable period for the fetus. This characteristic of a given teratogen, termed stage sensitivity, determines in part the abnormalities that will be observed. Three different stages are commonly recognized. The first extends from the period of fertilization through implantation during which time the embryo is largely composed of undifferentiated omnipotent cells with tremendous reparative capacity. Teratogens acting at this time commonly demonstrate an all on none effect whereby the teratogen is lethal or affects so few cells that the embryo can completely recover. The period of organogenesis is defined by organ formation and differentiation and is the period most sensitive to teratogenic effects and when most anatomic malformations occur. The period after organogenesis is primarily characterized by fetal growth and maturation. Teratogens that affect this period commonly produce cell depletion and growth retardation.
The data presented provide evidence supportive of specific inhibition of endothelial (constitutive NOS) NO release in the pathogenesis of the LRD produced by prenatal administration of L-NAME. The teratogenic effects of L-NAME in this study occurred beyond the period of organogenesis. The toxic effects of L-NAME were not be inhibited or prevented by concurrent administration of L-arginine which is indicative of a process specific for substrate competition. Inhibition of protein synthesis secondary to decreased cellular L-arginine uptake might affect limb growth, but this process would not be expected to be prevented by concurrent administration of NO donors as demonstrated in this study with SNAP and SNP.
Whereas many maturational changes are characterized by functional immaturity with a variable increase with age, the comparatively high NO release in newborns suggests that up-regulation may occur in the fetus concurrent with the mechanisms that govern up-regulation of maternal endothelial NO release. The fact that basal NO release is increased in both femoral and brachial vessels suggests that up-regulation of basal NO release is increased throughout the systemic circulation of the fetus and is not restricted to the hindlimb. LRD were dose-dependent, but were not influenced by the duration of treatment, occurring with equal frequency after 4, 7 (previous study), or 14 consecutive days of prenatal treatment (Fig. 1) . This result further substantiates a process specific for inhibition of endothelial NO release when one considers the pathophysiology by which L-NAME produces LRD. The histologic finding of hemorrhagic necrosis would suggest that L-NAME produced severe vasoconstriction leading to ischemic tissue death. Hemorrhagic necrosis reflecting cell death from isch- emia or infarction would be expected to occur over a relatively short period of time.
One of the primary goals of this study was to investigate mechanisms responsible for localization of vascular disruptions to the hindlimbs of affected offspring. The absence of disruptions after postnatal inhibition of NO release would seem to implicate the intrauterine environment. The most dramatic change that occurs with birth is the transfer of gas exchange from the placenta to the fetus as the lungs are expanded with the first breath. This brings about a substantial increase in oxygen tension and indicates that oxygen substrate availability may play a role in the pathogenesis of vascular disruption in hindlimbs.
The hindlimb circulation of the rat is unique in several respects. Recent studies by Davisson et al. (15) have demonstrated selective autonomic innervation in the hindlimb of the adult rat with very large regional increases in hindlimb blood flow in response to sympathetic activation or stress which can be selectively suppressed with either L-NAME or bretylium. In addition, Gardiner et al. (10) have demonstrated that the initial hypertensive response after i.v. administration of L-NAME is accompanied by marked vasoconstriction in the hindquarter, mesenteric, and renal vascular beds. With time, however, both the mesenteric and renal vasculature return to baseline tone, whereas the hindlimb circulation demonstrates a sustained vasoconstriction. The authors speculated that the hindlimb circulation is unable to compensate for inhibition of NO release. In addition, activation of the baroreceptor reflex in response to L-NAME-mediated hypertension would be ex-910 PIERCE ET AL. Comparative incidence of hindlimb disruption defects after either 7 d of prenatal L-NAME (1.0 mg/mL drinking waster) alone; L-NAME (1.0 mg/rnL) plus SNP (1, 3, and 10 pgkglmin, s.c.) and L-NAME (1.0 mg/mL) plus SNAP (1, 3 and 10 pgkglmin, s.c.) (n = 4-8 litterslgroup with 10-16 pups per litter). SNP and SNAP in a dose-dependent fashion reversed the disruptions. The asterisk (*) depicts a significant difference (p < 0.05) between prenatally L-NAME-treated alone vs L-NAME plus SNP and SNAP-treated fetuses. pected to cause a further decrease in hindlimb blood flow in response to inhibition of sympathetic tone.
Systemic hypertension in the fetus after prenatal administration of L-NAME may also play a role in the teratogenic effects observed. Hypertension has been implicated in the pathogenesis of LRD in the edema syndrome in chick embryos seen after exposure to moderated hypoxia (16). Moderate hypoxia in chick embryos produces an osmoregulatory disturbance with hypertension, hypervolemia, and death secondary to vessel rupture and hemorrhage. Leist and Grauwiler (17) have also reported the teratogenic effects of moderate hypoxia in rats produced by uterine artery clamping on gestational d 14. Litter size was dramatically reduced, and offspring demonstrated generalized edema and reduction defects of the snout, forelimbs, and hindlimbs. L-NAME produced no change in liter size, and the defects were strictly limited to hindlimbs. Although differences exist, it remains possible that hypertension is a common denominator in the pathogenesis of reduction defects after moderate hypoxia and L-NAME. It remains quite
